Chemistry:Cadisegliatin
From HandWiki
| |
| Names | |
|---|---|
| IUPAC name
[(2-{[Cyclohexyl(trans-4-propoxycyclohexyl)carbamoyl]amino}-1,3-thiazol-5-yl)sulfanyl]acetic acid
| |
| Identifiers | |
3D model (JSmol)
|
|
| ChEMBL | |
| ChemSpider | |
PubChem CID
|
|
| UNII | |
| |
| |
| Properties | |
| C21H33N3O4S2 | |
| Molar mass | 455.63 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
| Infobox references | |
Cadisegliatin (TTP399) is a liver-selective glucokinase activator. It is being developed by VTV Therapeutics for treatment of type 2 diabetes or type 1 diabetes as an adjunct to insulin.[1][2][3][4][5]
References
- ↑ Klein, Klara R.; Freeman, Jennifer L.R.; Dunn, Imogene; Dvergsten, Chris; Kirkman, M. Sue; Buse, John B.; Valcarce, Carmen; Buse, John B. et al. (1 April 2021). "The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 Diabetes". Diabetes Care 44 (4): 960–968. doi:10.2337/dc20-2684. PMID 33622669.
- ↑ Klein, Klara; Boeder, Schafer C.; Freeman, Jennifer L.; Madduri, Supradeep; Giovannetti, Erin R.; Valcarce, Carmen; Buse, John B.; Pettus, Jeremy (1 June 2022). "835-P: The Hepatoselective Glucokinase Activator (GKA) TTP399 Does Not Increase Risk of Ketoacidosis in Type 1 Diabetes (T1D)". Diabetes 71 (Supplement_1). doi:10.2337/db22-835-P.
- ↑ Klein, Klara R.; Boeder, Schafer C.; Freeman, Jennifer L. R.; Dunn, Imogene; Dvergsten, Chris; Madduri, Supradeep; Giovannetti, Erin R.; Valcarce, Carmen et al. (August 2022). "Impact of the hepatoselective glucokinase activator TTP399 on ketoacidosis during insulin withdrawal in people with type 1 diabetes". Diabetes, Obesity and Metabolism 24 (8): 1439–1447. doi:10.1111/dom.14697. PMID 35661378.
- ↑ Vella, Adrian; Freeman, Jennifer L. R.; Dunn, Imogene; Keller, Kit; Buse, John B.; Valcarce, Carmen (16 January 2019). "Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator". Science Translational Medicine 11 (475). doi:10.1126/scitranslmed.aau3441. PMID 30651321.
- ↑ Egan, Aoife; Vella, Adrian (2 September 2019). "TTP399: an investigational liver-selective glucokinase (GK) activator as a potential treatment for type 2 diabetes". Expert Opinion on Investigational Drugs 28 (9): 741–747. doi:10.1080/13543784.2019.1654993. PMID 31398075.
 |  |
